Across TCGA pan-cancer cohorts, MYT1L mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MYT1L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MYT1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYT1L is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC and LUAD are the cancer types where MYT1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYT1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−1.097	<.001	6	view →
LUAD	All	II,III,IV	−1.573	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MYT1L RNA expression & survival · all MYT1L data types